Light therapy could replace surgery for cervical precancer
NCT ID NCT07634497
First seen Jun 10, 2026 · Last updated Jun 11, 2026 · Updated 1 time
Summary
This study tests a light-activated drug (HAL-PDT) to treat cervical precancer (CIN2) in 500 women aged 18–50. The treatment is applied directly to the cervix and activated by a special light, aiming to destroy abnormal cells. The main goal is to see if the cervix returns to normal or has only mild changes after 6 months. This approach may offer a non-surgical option for women with this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 (CIN2) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.